Quest Diagnostics (DGX)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$212.26-0.56%
Close 2026-07-07 · 1-day change
Reading DGX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DGX free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading DGX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DGX free→QuarterlyIQ Insights · DGX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 14 valuation methods, at three horizons. Current price $212.26. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $212 DGX trades at 21× p/e, below its 27× p/e peer median, but our blended $203 fair value sits below the price. It's a high-confidence read. Analysts target $210–$225. Note: our $203 fair value sits below the entire analyst range ($210–$225). Not investment advice.
$210.00 – $225.00 (median $225.00) · 3 analysts · as of 2026-04-21
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $9.62/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $225.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $447.58 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $474.84 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $71.25 | — | — | TTM | high |
| graham number | 12M | $124.96 | — | — | TTM | high |
| Mgmt guidance | 12M | $257.48 | 26.6 | 9.68 | Mgmt | high |
| Peer EV/EBITDA | 12M | $243.07 | 15.3 | 19.12 | TTM | high |
| Peer P/FCF | 12M | $235.89 | 19.9 | 11.84 | TTM | high |
| Peer P/E | 12M | $269.72 | 26.6 | 10.14 | TTM | high |
| Peer P/S | 12M | $332.23 | 3.3 | 100.70 | TTM | high |
| PEG | 12M | $280.64 | 27.7 | 10.14 | TTM | high |
| residual income | 12M | $89.65 | — | — | TTM | high |
| Own P/E history | 12M | $193.27 | 19.1 | 10.14 | TTM | high |
| triangulated | 12M | $279.19 | 26.6 | 10.50 | Triangulated | high |
| Mgmt guidance | 3Y | $342.24 | 26.6 | 12.87 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $358.77 | 19.9 | 18.01 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $335.28 | 26.6 | 12.60 | Analyst | medium |
| Peer P/S | 3Y | $393.79 | 3.3 | 119.36 | guidance | medium |
| PEG | 3Y | $348.85 | 27.7 | 12.60 | Analyst | medium |
| Own P/E history | 3Y | $240.25 | 19.1 | 12.60 | Analyst | medium |
| Mgmt guidance | 5Y | $413.74 | 26.6 | 15.55 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $474.47 | 19.9 | 23.81 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $369.53 | 26.6 | 13.89 | Analyst | high |
| Peer P/S | 5Y | $434.02 | 3.3 | 131.55 | guidance | high |
| PEG | 5Y | $384.49 | 27.7 | 13.89 | Analyst | high |
| Own P/E history | 5Y | $264.79 | 19.1 | 13.89 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.